Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACT 1: Neoadjuvant HER2-targeted therapy in HER2-negative breast cancer with abnormal HER2 signaling
NCT03412643Phase 2Unknown
- Sponsor
- NSABP Foundation
- Start
- May 2018
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, pertuzumab in breast cancer, sponsored by NSABP Foundation. Status: unknown.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03412643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412643.